Shanghai Junshi Biosciences Co., Ltd. (688180) Stock Price, News, Quotes-Moomoo

CN Stock MarketDetailed Quotes

688180 Shanghai Junshi Biosciences Co., Ltd.

Watchlist

26.43
+0.23+0.88%

Market Closed Jan 23 15:00 CST

26.05BMarket Cap-14.44P/E (TTM)

Intraday

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Shanghai Junshi Biosciences Enters Contract for Cancer Drug Distribution in Europe
MT NewswiresJan 21 05:55 ET
Zhihui Hong Kong Stock Early Insights | Two Departments: Establish a pricing mechanism for public data resource authorization Operation. LINGBAO GOLD (03330) announces a profit warning.
The National Development and Reform Commission and the National Bureau of Statistics issued a notice on establishing a pricing mechanism for the authorized operation of public data resources.
Zhitong FinanceJan 20 19:05 ET
Announcement selection | New China Life Insurance expects a year-on-year profit increase of over 175% in 2024; LINGBAO GOLD is expected to see net income increase year-on-year by about 110% to 140%.
New China Life Insurance expects a year-on-year profit increase of over 175% in 2024; CHI MER LAND's annual sales exceed 42 billion yuan.
cls.cnJan 20 19:04 ET
JUNSHI BIO (01877) has signed a distribution and commercialization agreement for Trelagliptin with LEO Pharma.
JUNSHI BIO (01877) announced that recently, its wholly-owned subsidiary TopAlliance Bio...
Zhitong FinanceJan 20 07:49 ET
Express News | Shanghai Junshi Biosciences - Entering Into Distribution and Marketing Agreement With Leo Pharma
ReutersJan 20 07:46 ET
Express News | Junshi Biosciences Announces Commercialization Partnership With Leo Pharma for Toripalimab in Europe
ReutersJan 20 06:12 ET

Comments

Moomoo AI

Mar 5, 2024 16:54

The company's weak revenue trend, unprofitability, and rapid decline in share price reflect poor fundamentals. Last year's performance indicates unresolved challenges, worse than the annualized loss of 9% over the last half decade.

Further Weakness as Shanghai Junshi Biosciences (HKG:1877) Drops 3.2% This Week, Taking Three-year Losses to 83%

Spinee

Jan 17, 2024 02:21

HSI Plunge Once Deepens to 620 Pts; Pharmas In Sell-off

$Hang Seng Index (800000.HK)$ plunge deepened unceasingly after midday. It once stumbled 620 pts or 3.9% to bottom at 15,245, hitting an over-14-month low; last at 15,320, down 545 pts or 3.4%, with a total turnover of $88.5 billion.
Pharmaceuticals were sold off. $REMEGEN (09995.HK)$ once collapsed 27.5% to $22.8; last at $24.9, down 21%.
$CLOVER BIO-B (02197.HK)$ nosedived 9.6% to $0.47, hitting record low. $VIVA BIOTECH (01873.HK)$ ...

Moomoo AI

Jan 8, 2024 19:54

Despite Shanghai Junshi Biosciences' weak revenue growth, its P/S ratio aligns with industry peers, indicating investors may be overlooking limited growth expectations and paying a premium. However, this could risk investments as the weak revenue outlook may eventually impact share prices.

Shanghai Junshi Biosciences Co., Ltd.'s (HKG:1877) Price Is Out Of Tune With Revenues

Moomoo AI

Oct 27, 2023 19:26

Shanghai Junshi Biosciences carries rising debt yet has surplus liquid assets, offsetting risk. Despite having net cash, being a loss-maker might impact its financial health. Be cautious of investing until positive cash flow is seen.

Is Shanghai Junshi Biosciences (HKG:1877) Weighed On By Its Debt Load?

ETFWorldSavior

Jun 7, 2023 21:42

Columns Anxin International - Pharmaceutical Industry Biweekly Report: The results of Chinese medicine decoction pieces combined selection landing, 2023ASCO abstract released

Key points:
1. Hang Seng Index fell 2.57% in the first two weeks (2023/05/22 to 2023/06/02), with all 12 Hang Seng industries falling. Among them, the Hang Seng healthcare sector fell 1.51%, outperforming the Hang Seng Index by 1.06 percentage points, ranking third among the 12 Hang Seng industries
2. On May 22, the results of the f...

688180 Shanghai Junshi Biosciences Co., Ltd.

Trade Overview

Capital Trend

News

Comments

Trending Stocks